Drugs / AFFITOPE® PD01A
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02618941 | Feb 2016 → Feb 2017 | Parkinson disease | Affiris AG | Completed | No outcome recorded |
| Phase 1 | NCT02216188 | Aug 2014 → Aug 2015 | Parkinson disease | Affiris AG | Completed | No outcome recorded |
| Phase 1 | NCT01568099 | Feb 2012 → May 2014 | Parkinson disease | Affiris AG | Completed | No outcome recorded |
| Phase 1 | NCT02758730 | ? → Oct 2017 | Parkinson disease | Affiris AG | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFFITOPE PD01A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01568099 ↗ |
| Modality | Vaccine | “continued AFFITOPE® PD01A vaccinations” NCT02216188 ↗ |
| Route | Subcutaneous | “s.c. injection” NCT01568099 ↗ |